The NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional) from the National Institutes of Health (NIH) supports early-stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important problems relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director’s New Innovator Award Program complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The NIH Directors New Innovator Award Program is a component of the High-Risk, High-Reward Research Program of the NIH Common Fund. The grant provides 1.5 million USD for up to 5 years. Funding opportunity number: RFA-RM-23-005. Applications close on: August 18, 2023.